Matinas BioPharma Holdings Inc

NYSE:MTNB ISIN:US5768101058

Matinas BioPharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal ("LNC") platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn and Facebook.

     

News

VIDEO: Ellis Martin Report: Matinas BioPharma (NYSE:MTNB) Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

🕔5/20/2019 10:32:01 AM 6393

In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr. Jabbour will address Matinas' First Quarter 2019 Financial Results with an outlook toward the next 12 months.

Read Full Article

VIDEO: Ellis Martin Report-Spotlight: Matinas Biopharma's (NYSE:MTNB) Jerome Jabbour on the Company's Prescription Omega-3

🕔4/11/2019 2:43:03 PM 6972

Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma, (NYSE:MTNB).

Read Full Article

VIDEO: Matinas Biopharma's (NYSE:MTNB) Jerome Jabbour and Prescription Omega-3 for Potential Cardio-Vascular Disease Remediation

🕔9/26/2018 3:01:22 PM 14927

Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma (NYSEAMERICAN:MTNB).

Read Full Article
###

4,155 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 42) (Last 30 Days: 183) (Since Published: 4155) 

Company Data

    Headquarters
  • 1545 Route 206 South, Suite 302
    Bedminster, NJ 07921
  • Telephone
  • (908) 443-1860 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.matinasbiopharma.com
  • E:
  • info@matinasbiopharma.com